What is the clinical evidence from this study?

Study design: Observational. Population: Apical hypertrophic cardiomyopathy (n=7). Intervention: Clinical and metabolic evaluation. Primary outcome: Clinical, echocardiographic, and metabolic characteristics.

November 2, 1983European Heart Journal

Apical hypertrophic cardiomyopathy: clinical and metabolic studies

View Full Paper

Ask AI

Bookmark

Key result

Clinical and metabolic evaluation of patients with apical hypertrophic cardiomyopathy revealed apical thickness of 17.2 mm and progression to diffuse hypertrophy over 43 months.

Population

7 patients with concentric apical hypertrophy who underwent heart catheterization due to giant negative T…

Design

Case_series

Follow-up

mean 43 months

Authors

MBM BertrandLille’s Cardiology Hospital PTPierre Y. TilmantUniversité de Lille JLJ. M. LablancheUniversité de Lille

Discussion

Member takes

Implication

Apical HCM progression may occur; hypothesis-generating for metabolic drivers and surveillance needs.

Study Design

Type

Observational (n=7)

Structured PICO

Population

7 patients (5 men, 2 women) with concentric apical hypertrophy (hypertrophic non-obstructive cardiomyopathy) who underwent heart catheterization due to giant negative T waves in the precordial leads.

Intervention

Clinical, echocardiographic, angiographic, and metabolic evaluation (including atrial pacing with coronary arterial and venous lactate sampling).

Outcome

Echocardiographic, angiographic, and metabolic characteristics, and clinical/echocardiographic progression over follow-up.

Apical hypertrophic cardiomyopathy is characterized by a spade-like ventriculogram, metabolic abnormalities, and potential progression to concentric diffuse hypertrophy over time.

Cite This Study

Bertrand et al. (1983) conducted an observational in Apical hypertrophic cardiomyopathy (n=7). Clinical and metabolic evaluation was evaluated on Clinical, echocardiographic, and metabolic characteristics. Clinical and metabolic evaluation of patients with apical hypertrophic cardiomyopathy revealed apical thickness of 17.2 mm and progression to diffuse hypertrophy over 43 months.

synapsesocial.com/papers/6a0e4e8abc348c84f2fd9b1f https://doi.org/10.1093/eurheartj/4.suppl_f.127

Topics

Echocardiography Hypertrophic cardiomyopathy

View Full Paper

Ask AI

Bookmark

Apical hypertrophic cardiomyopathy: clinical and metabolic studies

Discussion

Member takes

Implication

Study Design

Structured PICO

Cite This Study

Topics

Apical hypertrophic cardiomyopathy: clinical and metabolic studies

Discussion

Member takes

Implication

Study Design

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider